Skip to main content
TipRanks
Go Ultimate75% OFF

Teladoc (TDOC) AI Stock Analysis

12,088 Followers
TDOC

Teladoc

(NYSE:TDOC)

Select Model
Rating:56Neutral
Price Target:$9.50▲(17.87% Upside)
Action:reiterated
Date:10/30/26

The score is driven primarily by improving operating efficiency and consistently positive free cash flow, supported by a constructive earnings update (EBITDA beat and raised guidance). These positives are tempered by ongoing net losses and weak revenue trajectory, while technicals show strong momentum but very overbought conditions. Valuation remains a headwind due to negative earnings and no dividend yield provided.

Positive Factors
Strong Cash GenerationConsistently positive operating and free cash flow gives Teladoc internal funding capacity for product investment, debt service, and strategic execution. The durable cash profile is especially important because it provides flexibility while the company works to convert improving operating performance into accounting profitability.
Negative Factors
Continued Net LossesPersistent net losses show that improved EBITDA and cash generation have not yet translated into bottom-line profitability. Until the company closes that gap, returns on equity remain negative and management has less evidence that the current operating model can produce durable shareholder earnings.

Teladoc Key Performance Indicators (KPIs)

Revenue by GeographyBreaks down sales by region (U.S. versus international), showing where revenue is concentrated and where growth opportunities or regulatory and currency risks exist. A heavy U.S. mix can imply steadier reimbursement while international growth offers upside—or added complexity.

$0.00$200.00M$400.00M$600.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

U.S. revenue has softened after its peak while international has been the fastest-growing geography — meaning Teladoc’s near-term growth now depends more on overseas and non-cash businesses. Management’s call confirms this: Integrated Care is driving international, with high single‑digit organic growth and expanding margins, but BetterHelp’s pivot to insurance and a pullback in international ad spend creates execution risk for global topline. In short, durable margin recovery hinges on Integrated Care scaling abroad while BetterHelp’s transition determines whether international growth stays broad‑based or concentrated.

Data provided by:The Fly

Teladoc (TDOC) vs. SPDR S&P 500 ETF (SPY)

-40%-20%0%20%40%TDOC+15.80%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.47B
Dividend Yield
―
Average Volume (3M)
4.19M
Price to Earnings (P/E)
-9.4
Beta (1Y)
1.62
Revenue Growth
-2.38%
EPS Growth
32.73%
Country
US
Employees
5,124
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and lo...

How the Company Makes Money

Teladoc primarily generates revenue by selling access to its virtual care platform and clinical services to business and institutional customers (such as employers and health plans) as well as through certain direct-to-consumer arrangements. A major...

Teladoc Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:17.15%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was positive overall. Management reported a solid third quarter with adjusted EBITDA above guidance, expanding margins, strong cash flow and liquidity, improved leverage, Integrated Care growth, and accelerating BetterHelp insurance traction. These positives outweighed the ongoing BetterHelp cash pay decline, lower total revenue and paying users, margin pressure, and continued uncertainty around the business transition.

Positive Updates

Adjusted EBITDA Beat Guidance and Expanded Year Over Year
Third-quarter consolidated adjusted EBITDA was $79 million, up 13.5% year over year and above the high end of guidance. Adjusted EBITDA margin increased approximately 200 basis points year over year to 13.1%.

Negative Updates

Consolidated Revenue Declined Year Over Year
Third-quarter consolidated revenue declined 3.4% year over year to $605 million.

Company Guidance

For 2026, Teladoc expects consolidated revenue of $2.39 billion to $2.44 billion, adjusted EBITDA of $277 million to $303 million, free cash flow of $135 million to $165 million, stock based compensation expense below $50 million, and a full year net loss per share of a loss of $0.95 per share to a loss of $0.75 per share; fourth-quarter consolidated revenue is expected to be $569 million to $615 million and adjusted EBITDA $74 million to $100 million. Integrated care revenue growth is expected to be 1.1% to 2.1%, adjusted EBITDA margin 16% to 16.6%, fourth-quarter revenue flat to up 3.8%, and fourth-quarter adjusted EBITDA margin 14.5% to 16.8%; BetterHelp revenue is expected to decline 16.1% to 12.9%, insurance revenue is expected to be $99 million to $105 million, adjusted EBITDA margin 2.7% to 4.3%, fourth-quarter revenue down 31.5% to down 18.5%, insurance revenue $32 million to $38 million, and adjusted EBITDA margin 9.2% to 15.1%. For 2027, Teladoc expects continued growth in insurance, a goal of sequential quarterly improvement over the course of 2027, and a goal of achieving an annualized revenue run rate of at least $200 million as we exit 2027; BetterHelp advertising and marketing spending is expected to decline in the mid to high-20% range for the full year in 2027.

Teladoc Financial Statement Overview

Summary

Cash flow is a clear strength (positive operating cash flow and free cash flow in all periods, including TTM), and margins are improving (higher gross margin and meaningfully better EBITDA margin). Offsetting this, TDOC remains unprofitable (negative net margin and ROE) and revenue momentum is weak/declining in the most recent period.

Income Statement

36Negative

Balance Sheet

54Neutral

Cash Flow

74Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.47B2.53B2.57B2.60B2.41B2.03B
Gross Profit1.81B1.76B1.82B1.84B1.66B1.38B
EBITDA236.09M147.30M174.06M138.22M50.32M-19.37M
Net Income-154.82M-200.32M-1.00B-220.37M-13.66B-428.79M
Balance Sheet
Total Assets2.78B2.86B3.52B4.39B4.70B17.73B
Cash, Cash Equivalents and Short-Term Investments849.91M781.08M1.30B1.12B918.18M896.02M
Total Debt1.04B1.04B1.58B1.59B1.59B1.28B
Total Liabilities1.48B1.47B2.03B2.07B2.39B1.69B
Stockholders Equity1.29B1.39B1.49B2.33B2.31B16.05B
Cash Flow
Free Cash Flow232.65M285.46M282.89M193.67M172.81M185.46M
Operating Cash Flow268.38M294.36M293.68M350.02M189.29M193.99M
Investing Cash Flow-143.25M-266.00M-124.05M-156.35M-167.74M-72.98M
Financing Cash Flow-53.00K-551.65M8.31M10.85M6.50M40.95M

Teladoc Technical Analysis

Technical Analysis SentimentPositive
Last Price8.06

Price Trends

50DMA6.85Positive
100DMA7.29Positive
200DMA6.64Positive

Market Momentum

MACD0.63Positive
RSI59.17Neutral
STOCH20.10Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Positive. The current price of 8.06 is below the 20-day moving average (MA) of 8.14, above the 50-day MA of 6.85, and above the 200-day MA of 6.64, indicating a bullish trend. The MACD of 0.63 indicates Positive momentum. The RSI at 59.17 is Neutral, neither overbought nor oversold. The STOCH value of 20.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TDOC.

Teladoc Risk Analysis

Teladoc disclosed 58 risk factors in its most recent earnings report. Teladoc reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.We use AI and machine learning to operate certain features of our programs and to enable certain business processes, which due to a changing regulatory landscape, could adversely affect our business, financial condition, and results of operations.Q4, 2025
2.In the U.S., a number of states have introduced healthcare transaction notification requirements which may impede our ability to grow through mergers, acquisitions, consolidations, and other transactions.Q4, 2024
3.The investment of our cash, cash equivalents and fixed income securities is subject to risks which may cause losses and affect the liquidity of these investments.Q4, 2023

Teladoc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TDOC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HNGEHNGE81Outperform$9.30B55.0650.47%―49.86%―
DOCSDOCS80Outperform$5.54B40.8914.81%―6.48%-43.66%
OMDAOMDA69Neutral$817.04M55.365.67%―43.34%―
TDOCTDOC56Neutral$1.47B-9.37-11.63%―-2.38%32.73%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AMWLAMWL51Neutral$189.94M-3.21-25.49%―-20.30%52.30%
VSEEVSEE40Underperform$175.37K-0.01-400.87%―-30.28%38.11%

* Healthcare Sector Average

Performance Comparison

-100%0%100%200%TDOCAMWLDOCSVSEEHNGEOMDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TDOC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TDOCTeladoc Inc.8.061.3019.23%
AMWLAmerican Well Corporation11.037.25191.80%
DOCSDoximity, Inc.30.67-15.75-33.93%
VSEEVsee Health, Inc.0.20-51.80-99.62%
HNGEHinge Health, Inc. Class A114.5369.17152.49%
OMDAOmada Health, Inc.13.17-5.00-27.52%

Teladoc Corporate Events

Executive/Board Changes

Teladoc Announces Chief Legal Officer Leadership Transition

Neutral
Sep 25, 2026

On September 24, 2026, Teladoc Health, Inc. announced that Chief Legal Officer and Secretary Adam C. Vandervoort had resigned with good reason under his executive severance agreement, effective November 1, 2026. He will continue to provide unpaid adv...

Business Operations and StrategyExecutive/Board Changes

Teladoc Health Appoints Michael Grasher as New CFO

Positive
Aug 31, 2026

On August 31, 2026, Teladoc Health appointed veteran financial executive Michael Grasher as Chief Financial Officer, while Charles Divita III remained Chief Executive Officer. Grasher brings more than three decades of experience in insurance and fina...

Executive/Board Changes

Teladoc Announces Upcoming Retirement of Longtime Board Director

Neutral
Aug 13, 2026

Teladoc Health, Inc., a leading telehealth provider serving consumers, employers and health plans, offers virtual medical and digital health services aimed at expanding access to care through remote technology. The company operates in the growing dig...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026